October 10, 2025Open Access

Lipoprotein(a) and Aortic Valve Stenosis: From Pathophysiology to Emerging Pharmacological Agents

View Full Paper

Ask AI

Bookmark

Elevated lipoprotein(a) levels are strongly linked to the progression of aortic valve stenosis, indicating potential therapeutic targets.
Current treatments for aortic valve stenosis are limited to surgical options, making the exploration of Lp(a)-targeted therapies crucial.
Emerging pharmacological agents, including antisense oligonucleotides, aim to lower Lp(a) levels, providing hope for new treatment approaches.
Ongoing clinical trials are evaluating the effectiveness of Lp(a)-specific therapies, which may significantly impact aortic valve stenosis management.

Discussion

No takes yet. Share an insight, caveat, or question.

This review highlights Lp(a) as a key factor in aortic valve stenosis, suggesting pharmacological agents may alter its progression.

Agnello et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark